4.5 Article

The Expression of ZNF268 and Its Role in The Cisplatin-based Chemoresistance of Breast Cancer

Journal

HELIYON
Volume 9, Issue 8, Pages -

Publisher

CELL PRESS
DOI: 10.1016/j.heliyon.2023.e18779

Keywords

Breast cancer; Cisplatin; Chemotherapy; Chemoresistance; ZNF268

Ask authors/readers for more resources

This study investigates the chemoresistance issue of cisplatin in breast cancer treatment. By analyzing breast cancer cell lines and patient samples, the study reveals that high expression of ZNF268 affects the efficacy of cisplatin and is closely associated with the prognosis of breast cancer patients. These findings have significant implications for predicting chemotherapy response and improving treatment survival rates in breast cancer patients.
Objective: Breast cancer is one of the most prevalent cancers in females worldwide and is one of the leading causes of cancer death and disability in women. Multiple therapies have been applied to breast cancer treatment; however, the long-term survival rate remains low. Although cisplatin has been widely utilized for cancer therapy, chemoresistance still influences the outcome. Methods: After collecting the breast cancer cell line MDA-MB-231 treated with or without cisplatin and sample information from The Cancer Genome Atlas Program (TCGA), we screened out their common parameters and influences on the prognoses of patients' potential targets. Surgical excisional tissue sections of patients with breast cancer who were admitted and treated in the Department of Breast and Thyroid Surgery, Liuzhou People's Hospital from 2017 to 2020 was collected and follow up. After a series of assays combined with clinical information, we tested the reliability of the target. Results: We found that a high expression level of ZNF268 in breast cancer cell lines significantly enhances the sensitivity to cisplatin, contrary to the effects of low expression. Furthermore, a significantly worse prognosis was observed in patients with a high expression of ZNF268 after cisplatin chemotherapy. Conclusion: The expression level of ZNF268 in breast cancer patients after cisplatin chemotherapy may become a potential target to predict the chemoresistance of patients to cisplatin. This study provides a novel idea for improving breast cancer treatment and survival rates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available